期刊
SEMINARS IN CANCER BIOLOGY
卷 22, 期 1, 页码 3-13出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2011.12.009
关键词
Monoclonal antibody; Cancer; Immunology; Drug resistance; Antibody dependent cellular cytotoxicity (ADCC); Complement dependent cytotoxicity (CDC); Antibody-like molecule
类别
资金
- NCI NIH HHS [R01 CA050633, P30 CA051008-19, T32 CA009686, R01 CA050633-23, P30 CA051008] Funding Source: Medline
Over the past decade, the clinical utility of monoclonal antibodies has been realized and antibodies are now a mainstay for the treatment of cancer. Antibodies have the unique capacity to target and kill tumor cells while simultaneously activating immune effectors to kill tumor cells through the complement cascade or antibody-dependent cellular cytotoxicity (ADCC). This multifaceted mechanism of action combined with target specificity underlies the capacity of antibodies to elicit anti-tumor responses while minimizing the frequency and magnitude of adverse events. This review will focus on mechanisms of action, clinical applications and putative mechanisms of resistance to monoclonal antibody therapy in the context of cancer. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据